nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial-Reference-Cited by-同舟云学术

nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial

Published:2018-08 Issue:8 Volume:29 Page:1763-1770
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Yardley D.A.,Coleman R.,Conte P.,Cortes J.,Brufsky A.,Shtivelband M.,Young R.,Bengala C.,Ali H.,Eakel J.,Schneeweiss A.,de la Cruz-Merino L.,Wilks S.,O’Shaughnessy J.,Glück S.,Li H.,Miller J.,Barton D.,Harbeck N.

Funder

Celgene Corporation

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/29/8/1763/25505158/mdy201.pdf

Reference27 articles.

1. Breast Cancer Facts & Figures 2015-2016;American Cancer Society;Atlanta, GA: American Cancer Society,2015

2. Triple-negative breast cancer: an unmet medical need;Hudis;Oncologist,2011

3. Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype;Bauer;Cancer,2007